Brainstorm Cell releases positive Phase II data in progressive MS at ECTRIMS

Shares of USA/Israel-based biotech Brainstorm Cell Therapeutics (Nasdaq: BCLI) were up 7% at $3.15 pre-market, but dropped back as regular trading came into play. The jump followed the company’s presentation of positive findings from a multicenter, open label clinical trial of NurOwn (autologous MSC-NTF cells) on progressive multiple sclerosis.

The results of the study, "Phase II Safety and Efficacy Study of Intrathecal MSC-NTF cells in Progressive Multiple Sclerosis,” were delivered in an oral presentation at the fully digital 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

The Phase II clinical trial was designed to evaluate intrathecal administration of NurOwn in participants with progressive MS. The study achieved the primary endpoint of safety and tolerability. It demonstrated a reduction of neuroinflammatory biomarkers and an increase in neuroprotective biomarkers in the cerebrospinal fluid (CSF) and consistent improvement across MS functional outcome measures, including measures of walking, upper extremity function, vision and cognition.